Molina Healthcare
MOH
$203.06
-4.41%
Molina Healthcare, Inc. is a managed care company that provides medical insurance plans primarily through Medicaid, Medicare, and Marketplace segments, serving over 5 million members with a focus on government-sponsored healthcare programs. As a leading Medicaid managed care provider, Molina differentiates itself through its deep state government contracts, with four states (California, New York, Texas, and Washington) accounting for over half of its enrollees. The current investor narrative centers on the company's recent earnings volatility, including a sharp decline in Q1 2026 net income due to elevated medical costs, and the broader sector's reaction to CMS Medicare payment increases that could improve revenue visibility. Additionally, the stock has experienced significant price swings, reflecting both optimism about growth opportunities and concerns over margin pressures in the Medicaid segment.…
MOH
Molina Healthcare
$203.06
Investment Opinion: Should I buy MOH Today?
Based on the analysis, Molina Healthcare is rated a Hold. The stock's valuation is attractive at a 13.6% discount to peers, but the recent earnings collapse and negative revenue growth warrant caution. The analyst consensus of Hold with an average target of $209.12, slightly below the current price, supports a neutral stance. The thesis is that Molina's diversified government programs provide long-term stability, but near-term margin pressures and operational challenges limit upside potential.
Sign up to view all
MOH 12-Month Price Forecast
The AI assessment is neutral, reflecting the balance between a low valuation and recent earnings deterioration. The stock's defensive beta and diversified government contracts provide some support, but the negative revenue growth and thin margins are concerning. The outlook hinges on margin recovery; if Q2 2026 shows improvement, the stance could upgrade to bullish, while continued weakness would reinforce a bearish view.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Molina Healthcare's 12-month outlook, with a consensus price target around $209.12 and implied upside of +3.0% versus the current price.
Average Target
$209.12
0 analysts
Implied Upside
+3.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$147 - $266
Analyst target range
Molina Healthcare is covered by 17 analysts, with a consensus recommendation of 'Hold' (mean rating of 2.74 on a 1-5 scale, where 1 is Strong Buy). The average target price is $209.12, which is 1.6% below the current price of $212.43, implying a slight downside of -1.6%. The distribution includes 5 Buy ratings, 8 Hold ratings, and 4 Sell ratings, reflecting a cautious sentiment. The low target of $147.00 suggests a potential downside of -30.8%, while the high target of $266.00 implies an upside of +25.2%, indicating a wide range of expectations. Recent institutional ratings have been predominantly neutral, with firms like TD Cowen, Truist, and Wells Fargo maintaining Hold/Equal Weight ratings, and Barclays reiterating Underweight, signaling that analysts are waiting for clearer signs of margin recovery before becoming more bullish.
Bulls vs Bears: MOH Investment Factors
Molina Healthcare presents a mixed picture: strong price momentum and a valuation discount are offset by a severe earnings downturn and cautious analyst sentiment. The bull case rests on the company's diversified government contracts and potential for margin recovery, while the bear case highlights the sharp Q1 profit collapse and negative revenue growth. Currently, the bearish evidence is stronger due to the immediate earnings deterioration, but the stock's low valuation and defensive beta offer some support. The key tension is whether the Q1 2026 weakness is a temporary blip or a structural issue; resolution of this will determine the stock's trajectory.
Bullish
- Strong 1-Year Price Performance: MOH has delivered a 33.08% return over the past year, significantly outperforming the S&P 500's 20.37% gain. This demonstrates robust market confidence and momentum, supported by a 56.95% surge over the last six months.
- Undervalued Relative to Peers: With a trailing PE of 19.43x versus the industry average of 22.5x, MOH trades at a 13.6% discount. This suggests the market is pricing in lower growth expectations, potentially offering value if the company can stabilize earnings.
- Diversified Government Program Portfolio: Molina's revenue is spread across Medicaid ($7.93B), Medicare ($1.52B), and Marketplace ($724M), reducing dependence on any single program. This diversification provides stability amid regulatory changes, as seen in the CMS Medicare payment boost.
- Positive Analyst High Target Upside: The analyst high target of $266.00 implies a 25.2% upside from the current price of $212.43. Even the average target of $209.12 is close to the current price, indicating limited downside risk from a consensus perspective.
Bearish
- Sharp Decline in Q1 2026 Net Income: Q1 2026 net income plummeted to $14 million from $298 million in Q1 2025, a 95% drop. This was driven by a gross margin contraction to 9.47% from 11.48%, reflecting elevated medical costs and operational challenges.
- Revenue Growth Turned Negative: Q1 2026 revenue declined 3.15% year-over-year to $10.796 billion, breaking a streak of consistent growth. This suggests potential membership losses or pricing pressures in Medicaid, a core segment.
- Analyst Consensus is Hold with Downside: The consensus rating is 'Hold' with a mean score of 2.74, and the average target price of $209.12 is 1.6% below the current price. This implies limited near-term upside and reflects cautious sentiment among analysts.
- Negative Free Cash Flow and PEG Ratio: The price-to-cash-flow ratio is -16.48, indicating negative free cash flow, and the PEG ratio is -0.34, signaling expected earnings declines. This raises concerns about the company's ability to sustain dividends or invest in growth.
MOH Technical Analysis
Molina Healthcare's stock has exhibited a strong uptrend over the past year, with a 1-year price change of +33.08%, significantly outperforming the S&P 500's +20.37% over the same period. The current price of $212.43 sits at approximately 87% of the 52-week range (low $121.06, high $244.89), indicating the stock is trading near the upper end of its range but below the peak. This positioning suggests momentum remains positive, though the stock has pulled back from its highs, potentially offering a buying opportunity if the uptrend resumes. The 6-month price change of +56.95% underscores the strong medium-term performance, while the 3-month change of +14.83% shows continued upward momentum, albeit at a slower pace.
Beta
0.75
0.75x market volatility
Max Drawdown
-44.0%
Largest decline past year
52-Week Range
$121-$245
Price range past year
Annual Return
+21.2%
Cumulative gain past year
| Period | MOH Return | S&P 500 |
|---|---|---|
| 1m | -9.9% | +4.0% |
| 3m | +10.1% | +5.3% |
| 6m | +42.4% | +12.6% |
| 1y | +21.2% | +20.1% |
| ytd | +13.8% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MOH Fundamental Analysis
Molina's revenue trajectory has been mixed, with the most recent quarter (Q1 2026) reporting revenue of $10.796 billion, a 3.15% decline year-over-year, breaking a streak of consistent growth. Over the past year, revenue grew from $10.499 billion in Q4 2024 to $11.475 billion in Q3 2025, but the latest quarter's decline suggests potential headwinds from Medicaid redeterminations or membership changes. The company's revenue segments show Medicaid Solutions as the dominant driver at $7.927 billion, followed by Medicare at $1.517 billion and Marketplace at $724 million, with other segments contributing $26 million. The revenue decline in Q1 2026 is concerning, but the company's diversified portfolio across government programs provides some stability.
Quarterly Revenue
$10.8B
2026-03
Revenue YoY Growth
-3.1%
YoY Comparison
Gross Margin
9.5%
Latest Quarter
Free Cash Flow
$251000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MOH Overvalued?
Given that Molina's trailing twelve-month net income is positive (though Q1 2026 was weak), the PE ratio is the appropriate primary valuation metric. The trailing PE is 19.43x, while the forward PE is 21.81x, indicating the market expects earnings to decline slightly in the coming year, which is consistent with the recent earnings weakness. Compared to the industry average PE of 22.5x (based on available data), Molina trades at a 13.6% discount, suggesting it is undervalued relative to peers. However, this discount may be justified by the company's lower net margin of 1.04% versus the industry average of 3.2%, reflecting its focus on lower-margin Medicaid business. Historically, Molina's PE has ranged from 12.09x to 123.43x over the past five years, with the current level near the lower end of that range, indicating the stock is trading at a historically attractive valuation.
PE
19.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are elevated due to Molina's thin net margin of 1.04% and negative free cash flow, as indicated by a price-to-cash-flow ratio of -16.48. The Q1 2026 net income of $14 million represents a 95% decline from the prior year, and the gross margin contracted to 9.47%, signaling potential cost pressures. Additionally, the debt-to-equity ratio of 0.97 suggests significant leverage, which could strain the balance sheet if earnings remain depressed. The company's reliance on government contracts exposes it to policy changes, such as Medicaid redeterminations, which could further impact revenue and margins.
FAQ
The key risks include: 1) Financial risk from thin margins (net margin 1.04%) and negative free cash flow, which could limit financial flexibility. 2) Operational risk from the Q1 2026 net income drop of 95% and revenue decline of 3.15%, indicating potential cost and membership issues. 3) Regulatory risk from changes in Medicaid and Medicare policies, which could impact reimbursement rates. 4) Competitive risk from larger managed care players, which could pressure market share. The most severe risk is a prolonged earnings downturn, which could lead to a de-rating toward the 52-week low of $121.06, a -43% downside.
The 12-month forecast is mixed. The base case (50% probability) sees the stock trading around the analyst average target of $209.12, implying a slight downside of -1.6%. The bull case (25% probability) targets $230-$266, driven by margin recovery and growth, while the bear case (25% probability) targets $147-$190, if earnings continue to deteriorate. The most likely scenario is the base case, assuming medical costs normalize and membership stabilizes. Key catalysts to watch are Q2 2026 earnings and any new contract wins.
MOH appears undervalued relative to peers, with a trailing PE of 19.43x versus the industry average of 22.5x, a 13.6% discount. However, this discount is justified by its lower net margin of 1.04% compared to the industry's 3.2%. Historically, the PE has ranged from 12.09x to 123.43x, and the current level is near the lower end, suggesting the market is pricing in pessimism. The valuation implies that investors expect earnings to decline, which aligns with the recent Q1 2026 performance.
MOH is a Hold, not a clear buy. The stock trades at a 13.6% discount to its industry PE, but the recent earnings collapse and negative revenue growth introduce significant risk. The analyst average target of $209.12 is slightly below the current price, implying limited upside. For risk-tolerant investors with a long-term horizon, the low valuation and defensive beta could make it an attractive entry point, but only if you believe the Q1 2026 weakness is temporary. Otherwise, waiting for clearer signs of margin recovery is prudent.
MOH is better suited for long-term investment due to its defensive beta of 0.754 and stable government-backed revenue streams. The stock's recent volatility (1-month change of -8.97%) makes it less attractive for short-term trading, as near-term earnings uncertainty could lead to further swings. For long-term investors, the low valuation and potential for margin recovery offer upside, but a minimum holding period of 3-5 years is recommended to ride out the current earnings cycle. The company pays no dividend, so returns will depend on capital appreciation.